CN Patent

CN114376970A — Etelcalcetide (AMG 416)的稳定的液体制剂

Assigned to Amgen Inc · Expires 2022-04-22 · 4y expired

What this patent protects

本申请涉及Etelcalcetide(AMG 416)的稳定的液体制剂。本发明提供一种包含钙敏感受体的肽激动剂(etelcalcetide，亦称为AMG416)、缓冲液和张力调节剂的液体制剂和制备和使用该制剂的方法。

USPTO Abstract

本申请涉及Etelcalcetide(AMG 416)的稳定的液体制剂。本发明提供一种包含钙敏感受体的肽激动剂(etelcalcetide，亦称为AMG416)、缓冲液和张力调节剂的液体制剂和制备和使用该制剂的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114376970A
Jurisdiction
CN
Classification
—
Expires
2022-04-22
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.